alpha-aminopyridine has been researched along with Malignant Mesothelioma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Alay, A; Aliagas, E; Aso, S; Busacca, S; Cordero, D; Dawson, A; Dorca, E; Escobar, I; Fennell, D; Gausachs, M; Hernández-Madrigal, M; Llatjós, R; Martínez-Iniesta, M; Muñoz-Pinedo, C; Nadal, E; Padrones, S; Palmero, R; Pros, E; Ramos, R; Ruffinelli, JC; Saigí, M; Sánchez-Céspedes, M; Sharkley, AJ; Solé, X; Varela, M; Vidal, A; Villanueva, A | 1 |
| Cheng, YY; Clarke, CJ; Johnson, B; Kao, S; Lee, K; Linton, A; McCaughan, BC; Rath, EM; Sarun, KH; Takahashi, K; Wang, Y; Yu, T; Yuen, ML; Zhuang, L | 1 |
| Anthony, S; Bajaj, A; Bhundia, V; Branson, A; Brookes, C; Darlison, L; Dawson, AG; Fennell, DA; Gaba, A; Greystoke, A; Hutka, M; King, A; Mohammed, S; Morgan, B; Nusrat, N; Poile, C; Richards, C; Scotland, M; Thomas, A; Wells-Jordan, P | 1 |
| Correale, P; Giannicola, R; Mutti, L; Nardone, V; Porta, C | 1 |
| Fennell, DA; Nusrat, N | 1 |
| Aerts, JG; Bezemer, K; Dammeijer, F; Hegmans, JP; Hendriks, RW; Kaijen-Lambers, ME; Lievense, LA; van Hall, T; van Nimwegen, M | 1 |
| Dhanasingh, I; Kanteti, R; Kindler, HL; Lennon, FE; Mambetsariev, B; Mirzapoiazova, T; Riehm, JJ; Salgia, R | 1 |
1 trial(s) available for alpha-aminopyridine and Malignant Mesothelioma
| Article | Year |
|---|---|
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
Topics: Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Diarrhea; Hemoptysis; Humans; Mesothelioma; Mesothelioma, Malignant; Pleural Neoplasms; Pulmonary Embolism; Respiratory Tract Infections; Sepsis; Thrombocytopenia; Vomiting | 2022 |
6 other study(ies) available for alpha-aminopyridine and Malignant Mesothelioma
| Article | Year |
|---|---|
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
Topics: Aged; Aminopyridines; Animals; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mesothelioma, Malignant; Mice; Piperazines; Protein Kinase Inhibitors; Pyridines; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |
The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM).
Topics: Aminopyridines; Antigens, CD; Cadherins; Cell Cycle; Cell Line, Tumor; ErbB Receptors; Focal Adhesion Kinase 1; Humans; Mesothelioma, Malignant; MicroRNAs; Protein Interaction Maps; Protein Kinase Inhibitors | 2021 |
Abemaciclib for malignant pleural mesothelioma.
Topics: Aminopyridines; Benzimidazoles; Humans; Mesothelioma, Malignant | 2022 |
Abemaciclib for malignant pleural mesothelioma - Authors' reply.
Topics: Aminopyridines; Benzimidazoles; Humans; Mesothelioma, Malignant; Pleural Neoplasms | 2022 |
Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
Topics: Aminopyridines; Animals; Antigens, Neoplasm; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Humans; Immunotherapy, Adoptive; Lung Neoplasms; Macrophages; Mesothelioma; Mesothelioma, Malignant; Neoplasm Invasiveness; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor | 2017 |
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crizotinib; Drug Synergism; Female; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Nude; Microtubules; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |